Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 5,277 matching trials from the live ClinicalTrials.gov search.

Filters: Gainesville, Florida Clear all

Conditions: Type 1 Diabetes (T1D)
Interventions: L. johnsonii Probiotic, Placebo Capsule; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 45 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: SHP465 12.5mg capsules (one capsule daily), Placebo, SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily); Drug · Other
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 45
States / cities: Encino, California • Los Alamitos, California • Newport Beach, California + 40 more

Conditions: Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus
Interventions: AP-SA02, Placebo; Biological · Other
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 23
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 19 more

Conditions: NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions: Efruxifermin, Placebo; Drug
Lead sponsor: Akero Therapeutics, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 2,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 169
States / cities: Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 141 more

Conditions: Autism Spectrum Disorder
Interventions: Occupational Therapy Intervention; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 6 Years to 9 Years · Male only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Systemic Lupus Erythematosus
Interventions: BMS-986165; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 25
States / cities: Birmingham, Alabama • El Cajon, California • Torrance, California + 21 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Xaluritamig, Abiraterone, Enzalutamide, Cabazitaxel; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 707 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 42
States / cities: Birmingham, Alabama • Duarte, California • Fullerton, California + 32 more

Conditions: Type 2 Diabetes
Interventions: Tirzepatide, Antihyperglycemic medication; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 32
States / cities: Birmingham, Alabama • Canoga Park, California • Huntington Park, California + 29 more

Conditions: Head and Neck Cancer
Interventions: filgrastim, cisplatin, docetaxel, fluorouracil, paclitaxel, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 125
States / cities: Birmingham, Alabama • Mobile, Alabama • Hot Springs, Arkansas + 96 more

Conditions: Peripheral Arterial Disease
Interventions: Shockwave Lithoplasty® Peripheral Lithoplasty System, Medtronic IN.PACT (DCB); Device · Drug
Lead sponsor: Shockwave Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 40
States / cities: Little Rock, Arkansas • Palo Alto, California • Aurora, Colorado + 33 more

Conditions: Muscular Dystrophy, Duchenne
Interventions: Magnetic Resonance Imaging (MRI), Pulmonary Function Testing (PFT), Metabolic Exercise Testing using stationary bicycle, Echocardiogram; Other
Lead sponsor: University of Florida; Other
Eligibility: 5 Years to 15 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Cancer
Interventions: Endoscopic Ultrasound (EUS) for fiducial placement; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Unstable Angina, Coronary Atherosclerosis, Coronary Restenosis
Interventions: Serine proteinase-1 (Serp-1); Drug
Lead sponsor: Viron Therapeutics Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Gainesville, Florida • Grand Rapids, Michigan

Conditions: Endometriosis
Interventions: Placebo, OBE2109; Drug
Lead sponsor: ObsEva SA; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 71
States / cities: Chandler, Arizona • Scottsdale, Arizona • Arcadia, California + 59 more

Conditions: Inguinal Hernia, Premature Birth of Newborn
Interventions: IH repair before NICU discharge, IH repair at 55-60 weeks post-menstrual age; Procedure
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: Up to 37 Weeks
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 40
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 33 more

Conditions: Pain, Postoperative
Interventions: Surgical patients' clinical progression, Genetic markers; Behavioral · Genetic
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant, Lip and Oral Cavity Squamous Cell Carcinoma, p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oral Cavity Verrucous Carcinoma, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oral Cavity Verrucous Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions: Cisplatin, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis; Drug · Radiation · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 679
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 450 more

Conditions: Motility Disorder
Interventions: esophageal manometry, Gatorade, Supine position, Semi-recumbent position, Sitting, Standing; Procedure · Dietary Supplement · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Systemic Lupus Erythematosus
Interventions: BMS-986165, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 363 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 55
States / cities: Birmingham, Alabama • Little Rock, Arkansas • El Cajon, California + 45 more

Conditions: Chronic Pain
Interventions: Abbott Spinal Cord Stimulation (SCS) Systems (Apple Watch® & Oura™ Ring); Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 7
States / cities: Carlsbad, California • Santa Rosa, California • Gainesville, Florida + 4 more

Conditions: Cold Exposure
Interventions: Oxytocin nasal spray, Placebo nasal spray; Drug
Lead sponsor: Florida Institute for Human and Machine Cognition; Other
Eligibility: 18 Years to 39 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Gainesville, Florida • Pensacola, Florida

Conditions: Breast Cancer
Interventions: metformin hydrochloride, placebo; Drug · Other
Lead sponsor: Canadian Cancer Trials Group; Network
Eligibility: 18 Years to 74 Years
Enrollment: 3,649 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 280
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Scottsdale, Arizona + 213 more

Conditions: Kidney Transplantation
Interventions: mycophenolate mofetil [CellCept], Cyclosporine or tacrolimus; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years to 75 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 20
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 17 more

Conditions: Diabetes Mellitus, Type I
Interventions: blood draw or cheek swab; Other
Lead sponsor: GentiBio, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: San Francisco, California • Gainesville, Florida • Boston, Massachusetts + 2 more

Search by objective public record fields.

Lactobacillus Johnsonii Supplementation in Adults With T1D

Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)

Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

Sensory Intervention for Children With Autism

Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery

Shockwave Medical Peripheral Lithoplasty System Study for PAD (Disrupt PAD III)

Assessment of Cardiopulmonary Function in Duchenne Muscular Dystrophy

Endoscopic Ultrasound-Guided Fiducial Placement for Stereotactic Body Radiotherapy

Serp-1 for the Treatment of Acute Coronary Syndrome

A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis

Timing of Inguinal Hernia Repair in Premature Infants

TEMporal PostOperative Pain Signatures

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

High Resolution Manometry for Swallowing

An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus

Spinal Cord Stimulation Trial to Permanent Prediction

Oxytocin on Cold Water Task Performance and Recovery

A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer

Pharmacogenetic Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.

HLA Demographics Study in Adults With Type 1 Diabetes